The University of Southampton
University of Southampton Institutional Repository

Oral Chinese herbal medicine (CHM) as an adjuvant treatment during chemotherapy for non-small cell lung cancer: a systematic review

Oral Chinese herbal medicine (CHM) as an adjuvant treatment during chemotherapy for non-small cell lung cancer: a systematic review
Oral Chinese herbal medicine (CHM) as an adjuvant treatment during chemotherapy for non-small cell lung cancer: a systematic review
Background: non-small cell lung cancer (NSCLC) remains a major global health problem because of its prevalence and poor prognosis. Treatment options are limited and there is a need to explore alternatives. This systematic review evaluates the role of Chinese herbal medicine (CHM) in association with chemotherapy for NSCLC.

Methods: english and Chinese databases were searched for RCTs comparing CHM with conventional biomedical treatment or placebo. Papers were reviewed systematically and data were analysed using standard Cochrane software Revman 5.

Results: fifteen Chinese trials involving 862 participants met the inclusion criteria. All trials were of poor quality with a considerable risk of bias. There was a significant improvement in quality of life (QoL) (increased Karnofsky Performance Status) (RR 1.83, 95% CI 1.41-2.38, p<0.00001 for both stages III, IV only NSCLC and all stages NSCLC) and less anaemia (RR 0.37, 95% CI 0.15-0.91, p=0.03 for stages III, IV only NSCLC; p=0.005 for all stages NSCLC) and neutropenia (RR 0.42, 95% CI 0.22-0.82, p=0.01 for stages III, IV only NSCLC; p<0.00001 for all stages NSCLC) when CHM is combined with chemotherapy compared to chemotherapy alone. There was no significant difference in short term effectiveness and limited inconclusive data concerning long term survival. Five promising herbs have been identified.

Conclusion: it is possible that oral CHM used in conjunction with chemotherapy may improve QoL in NSCLC. This needs to be examined further with more rigorous methodology.
Chinese herbal medicine, systematic review, complementary medicine, non-small cell lung cancer
0169-5002
137-145
Chen, Sisi
9510418a-cae8-468c-a30e-7329d8bd18c8
Flower, Andrew
5256a2c8-6e74-49be-acc8-463ed3c18c6a
Ritchie, Andrew
98e87f92-33f5-42d8-9f00-8dec3c9bd757
Liu, Jianping
4699004b-2872-49f2-b2f9-f90a061a29db
Molassiotis, Alex
f4f18817-07cb-48ca-a51e-9504aa886a79
He, Yu
50c6db3a-8a30-4d25-b97f-bf79cdc68175
Lewith, George
0fc483fa-f17b-47c5-94d9-5c15e65a7625
Chen, Sisi
9510418a-cae8-468c-a30e-7329d8bd18c8
Flower, Andrew
5256a2c8-6e74-49be-acc8-463ed3c18c6a
Ritchie, Andrew
98e87f92-33f5-42d8-9f00-8dec3c9bd757
Liu, Jianping
4699004b-2872-49f2-b2f9-f90a061a29db
Molassiotis, Alex
f4f18817-07cb-48ca-a51e-9504aa886a79
He, Yu
50c6db3a-8a30-4d25-b97f-bf79cdc68175
Lewith, George
0fc483fa-f17b-47c5-94d9-5c15e65a7625

Chen, Sisi, Flower, Andrew, Ritchie, Andrew, Liu, Jianping, Molassiotis, Alex, He, Yu and Lewith, George (2010) Oral Chinese herbal medicine (CHM) as an adjuvant treatment during chemotherapy for non-small cell lung cancer: a systematic review. Lung Cancer, 68, 137-145. (doi:10.1016/j.lungcan.2009.11.008).

Record type: Article

Abstract

Background: non-small cell lung cancer (NSCLC) remains a major global health problem because of its prevalence and poor prognosis. Treatment options are limited and there is a need to explore alternatives. This systematic review evaluates the role of Chinese herbal medicine (CHM) in association with chemotherapy for NSCLC.

Methods: english and Chinese databases were searched for RCTs comparing CHM with conventional biomedical treatment or placebo. Papers were reviewed systematically and data were analysed using standard Cochrane software Revman 5.

Results: fifteen Chinese trials involving 862 participants met the inclusion criteria. All trials were of poor quality with a considerable risk of bias. There was a significant improvement in quality of life (QoL) (increased Karnofsky Performance Status) (RR 1.83, 95% CI 1.41-2.38, p<0.00001 for both stages III, IV only NSCLC and all stages NSCLC) and less anaemia (RR 0.37, 95% CI 0.15-0.91, p=0.03 for stages III, IV only NSCLC; p=0.005 for all stages NSCLC) and neutropenia (RR 0.42, 95% CI 0.22-0.82, p=0.01 for stages III, IV only NSCLC; p<0.00001 for all stages NSCLC) when CHM is combined with chemotherapy compared to chemotherapy alone. There was no significant difference in short term effectiveness and limited inconclusive data concerning long term survival. Five promising herbs have been identified.

Conclusion: it is possible that oral CHM used in conjunction with chemotherapy may improve QoL in NSCLC. This needs to be examined further with more rigorous methodology.

Full text not available from this repository.

More information

Published date: 2010
Keywords: Chinese herbal medicine, systematic review, complementary medicine, non-small cell lung cancer

Identifiers

Local EPrints ID: 73657
URI: https://eprints.soton.ac.uk/id/eprint/73657
ISSN: 0169-5002
PURE UUID: 7d883cca-02a8-48bd-88ae-082667bc21a8

Catalogue record

Date deposited: 16 Mar 2010
Last modified: 18 Jul 2017 23:48

Export record

Altmetrics

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×